Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Pfizer Presents Interim Analysis From Phase 3 Trial In Advanced BRAFV600E-Mutant Metastatic Colorectal Cancer

By John F. Heerdink, Jr.

Pfizer (PFE)  is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. Recently, Pfizer announced the results of the interim analysis of the Phase 3 BEACON CRC trial with a combination of BRAFTOVI® (encorafenib), MEKTOVI® (binimetinib), and cetuximab (BRAFTOVI Triplet) with patients suffering from advanced BRAFV600E-mutant metastatic colorectal cancer.

The results were reported to have promised significant improvement for the BRAFTOVI Triplet and BRAFTOVI Doublet combination in comparison to cetuximab plus irinotecan-containing regimens along with analysis of the effectiveness and safety of the BRAFTOVI Triplet in comparison to the BRAFTOVI Doublet. The data was represented at the 2019 European Society for Medical Oncology Congress in Barcelona, Spain last month. The results of the BEACON CRC trial is scheduled to be submitted in the fourth quarter of 2019 by Pfizer for marketing approval in the U.S. The use of BRAFTOVI, MEKTOVI and cetuximab for the treatment of patients suffering from with BRAFV600E-mutant mCRC is investigational and is yet to be approved by the FDA.

“We are pleased to share these data from the BEACON CRC trial with the oncology community. With no approved therapies currently indicated specifically for BRAF-mutant mCRC, we believe that the evidence so far shows encouraging potential for the BRAFTOVI Triplet to make a meaningful impact on the lives of those living with this disease,” stated Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development.

To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.


Post View Count : 366
(Read Original Story: Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer in Business Wire)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us